$NXTC

Nextcure Inc

  • NASDAQ
  • Biotechnology
  • Health Technology

PRICE

$1.76 ▼-0.565%

Extented Hours

VOLUME

17,913

DAY RANGE

1.66 - 1.77

52 WEEK

1.16 - 5.27

Join Discuss about NXTC with like-minded investors

profile
@thegiz18 #ivtrades
recently

$NXTC upgrade, $19 target

72 Replies 13 👍 14 🔥

profile
@thegiz18 #ivtrades
recently

$NXTC has some clear air above yesterdays highs

59 Replies 9 👍 11 🔥

profile
@thegiz18 #ivtrades
recently

$NXTC finally breaking free from prior call out

131 Replies 11 👍 15 🔥

profile
@thegiz18 #ivtrades
recently

$NXTC has been catching some bids, above 12.80 has lots of clear air

150 Replies 11 👍 14 🔥

TR
@TraderJack #ivtrades
recently

$NXTC is not vaccine play

44 Replies 13 👍 6 🔥

TR
@TraderJack #ivtrades
recently

Still in $BMRN, $NBIX, $AZN, $NXTC, $EBS, and $PFE. It is ok for them down today

139 Replies 8 👍 6 🔥

profile
@thegiz18 #ivtrades
recently

$NXTC upgraded with $17 price target after Mondays bloodbath

131 Replies 9 👍 13 🔥

profile
@thegiz18 #ivtrades
recently

$NXTC getting spanked, announced not moving forward on a stage 2 trial on one of their cancer drug candidates, down nearly 30% premarket

100 Replies 13 👍 12 🔥

Key Metrics

Market Cap

47.88 M

Beta

0.75

Avg. Volume

55.15 K

Shares Outstanding

27.83 M

Yield

0%

Public Float

0

Next Earnings Date

2023-08-03

Next Dividend Date

Company Information

nextcure, inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. its lead product candidate is nc318, which is in phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. the company is also developing nc410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called leukocyte-associated immunoglobulin-like receptor 1. its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the b7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. nextcure, inc. has a license agreement with yale university; and a research and development col

CEO: Michael Richman

Website:

HQ: 9000 Virginia Manor Rd Ste 200 Beltsville, 20705-4214 Maryland

Related News